Nifedipine cream topical application — Competitive Intelligence Brief

Nifedipine cream topical application (Nifedipine cream topical application) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium channel blocker (dihydropyridine). Area: Cardiovascular / Dermatology.

phase 3 Calcium channel blocker (dihydropyridine) L-type voltage-gated calcium channel Cardiovascular / Dermatology Small molecule

Target snapshot

Nifedipine cream topical application (Nifedipine cream topical application) — Western Galilee Hospital-Nahariya. Nifedipine is a calcium channel blocker that relaxes vascular smooth muscle and improves blood flow when applied topically to affected tissues.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nifedipine cream topical application TARGET	Nifedipine cream topical application	Western Galilee Hospital-Nahariya	phase 3	Calcium channel blocker (dihydropyridine)	L-type voltage-gated calcium channel
Amlodipine/Atorvastatin	Amlodipine/Atorvastatin	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	marketed	Calcium channel blocker / HMG-CoA reductase inhibitor (statin) combination	L-type voltage-gated calcium channels / HMG-CoA reductase
Lercanidipine/enalapril fixed combination	Lercanidipine/enalapril fixed combination	Meir Medical Center	marketed	Calcium channel blocker / ACE inhibitor combination	L-type voltage-gated calcium channels; Angiotensin-converting enzyme (ACE)
Losartan/amlodipine or losartan/hydrochlorothiazide	Losartan/amlodipine or losartan/hydrochlorothiazide	Yokohama City University Medical Center	marketed	Angiotensin II receptor blocker combination (ARB + calcium channel blocker or ARB + thiazide diuretic)	Angiotensin II type 1 receptor (AT1R); L-type voltage-gated calcium channels (amlodipine) or sodium-chloride cotransporter (hydrochlorothiazide)
Amlodipine placebos	Amlodipine placebos	Shenzhen Ausa Pharmed Co.,Ltd	marketed	Calcium channel blocker (dihydropyridine)	L-type voltage-gated calcium channel
amlodipine/hydrochlorothiazide	amlodipine/hydrochlorothiazide	Shanghai Jiao Tong University School of Medicine	marketed	Calcium channel blocker / Thiazide diuretic combination	L-type voltage-gated calcium channel (amlodipine); Sodium-chloride cotransporter (hydrochlorothiazide)
Amlodipine plus Hydrochlorothiazide	Amlodipine plus Hydrochlorothiazide	University of Abuja	marketed	Calcium channel blocker + thiazide diuretic combination	L-type voltage-gated calcium channel (amlodipine); sodium-chloride cotransporter (hydrochlorothiazide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium channel blocker (dihydropyridine) class)

1. Bayer · 2 drugs in this class
2. Beijing Tiantan Hospital · 2 drugs in this class
3. GlaxoSmithKline · 1 drug in this class
4. Guangzhou First People's Hospital · 1 drug in this class
5. Organon and Co · 1 drug in this class
6. Peking University First Hospital · 1 drug in this class
7. Pfizer Inc. · 1 drug in this class
8. SK Chemicals Co., Ltd. · 1 drug in this class
9. Shanghai Jiao Tong University School of Medicine · 1 drug in this class
10. Shanghai Shyndec Pharmaceutical Co., Ltd. · 1 drug in this class